XML 97 R40.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Identifiable Intangible Assets and Goodwill (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract] |
Schedule of Finite-Lived Intangible Assets |
The following table provides the components of Identifiable intangible assets:
|  | December 31, 2018 |  | December 31, 2017
(MILLIONS OF DOLLARS) |  | Gross Carrying Amount |  |  | Accumulated Amortization |  |  | Identifiable Intangible Assets, less Accumulated Amortization |  |  | Gross Carrying Amount |  |  | Accumulated Amortization |  |  | Identifiable Intangible Assets, less Accumulated Amortization |
Finite-lived intangible assets |  |  |  |  |  |  |  |  |  |  |  |
Developed technology rights(a) |  | $ | 89,430 |  |  | $ | (58,895 | ) |  | $ | 30,535 |  |  | $ | 89,550 |  |  | $ | (54,785 | ) |  | $ | 34,765 |
Brands(a) |  | 923 |  |  | (708 | ) |  | 215 |  |  | 2,134 |  |  | (1,152 | ) |  | 982 |
Licensing agreements and other |  | 1,436 |  |  | (1,140 | ) |  | 296 |  |  | 1,911 |  |  | (1,096 | ) |  | 815 |
|  | 91,788 |  |  | (60,743 | ) |  | 31,045 |  |  | 93,595 |  |  | (57,033 | ) |  | 36,562 |
Indefinite-lived intangible assets |  |  |  |  |  |  |  |  |  |  |  |
Brands and other(a) |  | 1,994 |  |  |  |  |  | 1,994 |  |  | 6,929 |  |  |  |  |  | 6,929 |
IPR&D(a) |  | 2,171 |  |  |  |  |  | 2,171 |  |  | 5,249 |  |  |  |  |  | 5,249 |
|  | 4,165 |  |  |  |  |  | 4,165 |  |  | 12,179 |  |  |  |  |  | 12,179 |
Identifiable intangible assets(b) |  | $ | 95,954 |  |  | $ | (60,743 | ) |  | $ | 35,211 |  |  | $ | 105,774 |  |  | $ | (57,033 | ) |  | $ | 48,741 |
(a) | The changes in the gross carrying amount of Developed technology rights, Brands, Brands and other and IPR&D primarily reflect (i) the reclassification of $6.1 billion of Brands and Brands and other to Assets held for sale during the fourth quarter of 2018 (see Note 2C), (ii) the transfer of $2.7 billion from IPR&D to Developed technology rights to reflect the approval of Xtandi in the U.S. for the treatment of men with non-metastatic castration-resistant prostate cancer, which is being developed through a collaboration with Astellas (see Note 2A), (iii) $240 million of Developed technology rights recorded in connection with the EU approval of Mylotarg (see Note 7E), as well as impairments of $2.9 billion of Developed technology rights (see Note 4).
(b) | The decrease in I dentifiable intangible assets, less accumulated amortization, is primarily due to the reclassification of $5.8 billion of intangible assets, net, ($6.3 billion total gross carrying amount) to Assets held for sale during the fourth quarter of 2018 (see Note 2C) and amortization and impairments, partially offset by additions, mainly consisting of $240 million of Developed technology rights recorded in connection with the EU approval of Mylotarg (see Note 7E).
Our identifiable intangible assets are associated with the following, as a percentage of total identifiable intangible assets, less accumulated amortization:
|  | December 31, 2018
|  | IH |  | EH |  | WRD
Developed technology rights |  | 76 | % |  | 24 | % |  | — |
Brands, finite-lived |  | — |  |  | 100 | % |  | — |
Brands, indefinite-lived |  | — |  |  | 100 | % |  | — |
IPR&D |  | 65 | % |  | 18 | % |  | 17 | %
Schedule of Indefinite-Lived Intangible Assets |
The following table provides the components of Identifiable intangible assets:
|  | December 31, 2018 |  | December 31, 2017
(MILLIONS OF DOLLARS) |  | Gross Carrying Amount |  |  | Accumulated Amortization |  |  | Identifiable Intangible Assets, less Accumulated Amortization |  |  | Gross Carrying Amount |  |  | Accumulated Amortization |  |  | Identifiable Intangible Assets, less Accumulated Amortization |
Finite-lived intangible assets |  |  |  |  |  |  |  |  |  |  |  |
Developed technology rights(a) |  | $ | 89,430 |  |  | $ | (58,895 | ) |  | $ | 30,535 |  |  | $ | 89,550 |  |  | $ | (54,785 | ) |  | $ | 34,765 |
Brands(a) |  | 923 |  |  | (708 | ) |  | 215 |  |  | 2,134 |  |  | (1,152 | ) |  | 982 |
Licensing agreements and other |  | 1,436 |  |  | (1,140 | ) |  | 296 |  |  | 1,911 |  |  | (1,096 | ) |  | 815 |
|  | 91,788 |  |  | (60,743 | ) |  | 31,045 |  |  | 93,595 |  |  | (57,033 | ) |  | 36,562 |
Indefinite-lived intangible assets |  |  |  |  |  |  |  |  |  |  |  |
Brands and other(a) |  | 1,994 |  |  |  |  |  | 1,994 |  |  | 6,929 |  |  |  |  |  | 6,929 |
IPR&D(a) |  | 2,171 |  |  |  |  |  | 2,171 |  |  | 5,249 |  |  |  |  |  | 5,249 |
|  | 4,165 |  |  |  |  |  | 4,165 |  |  | 12,179 |  |  |  |  |  | 12,179 |
Identifiable intangible assets(b) |  | $ | 95,954 |  |  | $ | (60,743 | ) |  | $ | 35,211 |  |  | $ | 105,774 |  |  | $ | (57,033 | ) |  | $ | 48,741 |
(a) | The changes in the gross carrying amount of Developed technology rights, Brands, Brands and other and IPR&D primarily reflect (i) the reclassification of $6.1 billion of Brands and Brands and other to Assets held for sale during the fourth quarter of 2018 (see Note 2C), (ii) the transfer of $2.7 billion from IPR&D to Developed technology rights to reflect the approval of Xtandi in the U.S. for the treatment of men with non-metastatic castration-resistant prostate cancer, which is being developed through a collaboration with Astellas (see Note 2A), (iii) $240 million of Developed technology rights recorded in connection with the EU approval of Mylotarg (see Note 7E), as well as impairments of $2.9 billion of Developed technology rights (see Note 4).
(b) | The decrease in I dentifiable intangible assets, less accumulated amortization, is primarily due to the reclassification of $5.8 billion of intangible assets, net, ($6.3 billion total gross carrying amount) to Assets held for sale during the fourth quarter of 2018 (see Note 2C) and amortization and impairments, partially offset by additions, mainly consisting of $240 million of Developed technology rights recorded in connection with the EU approval of Mylotarg (see Note 7E).
Our identifiable intangible assets are associated with the following, as a percentage of total identifiable intangible assets, less accumulated amortization:
|  | December 31, 2018
|  | IH |  | EH |  | WRD
Developed technology rights |  | 76 | % |  | 24 | % |  | — |
Brands, finite-lived |  | — |  |  | 100 | % |  | — |
Brands, indefinite-lived |  | — |  |  | 100 | % |  | — |
IPR&D |  | 65 | % |  | 18 | % |  | 17 | %
Schedule of Expected Amortization Expense |
The following table provides the annual amortization expense expected for the years 2019 through 2023:
(MILLIONS OF DOLLARS) |  | 2019 |  |  | 2020 |  |  | 2021 |  |  | 2022 |  |  | 2023 |
Amortization expense |  | $ | 4,581 |  |  | $ | 3,552 |  |  | $ | 3,467 |  |  | $ | 3,217 |  |  | $ | 2,920 |
Schedule of Goodwill |
The following table provides the components of and changes in the carrying amount of Goodwill:
(MILLIONS OF DOLLARS) |  | IH |  |  | EH |  |  | Total |
Balance, January 1, 2017 |  | $ | 30,134 |  |  | $ | 24,315 |  |  | $ | 54,449 |
Additions(a) |  | 572 |  |  | 92 |  |  | 664 |
Other(b) |  | 435 |  |  | 404 |  |  | 840 |
Balance, December 31, 2017 |  | 31,141 |  |  | 24,811 |  |  | 55,952 |
Other(c) |  | (2,264 | ) |  | (277 | ) |  | (2,541 | )
Balance, December 31, 2018 |  | $ | 28,877 |  |  | $ | 24,534 |  |  | $ | 53,411 |
(a) | IH additions primarily represent measurement period adjustments related to our Medivation acquisition, and EH additions relate to our acquisition of AstraZeneca’s small molecule anti-infectives business (see Note 2A).
(b) | Primarily reflects the impact of foreign exchange and an adjustment of our estimate of goodwill associated with the HIS net assets sold.
(c) | Primarily reflects the impact of the reclassification of $2.0 billion to Assets held for sale during the fourth quarter of 2018 (see Note 2C), foreign exchange and the contribution of the allogeneic CAR T developmental program assets and operations to Allogene that constituted a business for accounting purposes (see Note 2B).

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275 + Details
Name: | us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267 + Details
Name: | us-gaap_ScheduleOfGoodwillTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 3 -Subparagraph (b),(d) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 + Details
Name: | us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 + Details
Name: | us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration